Slides
Page 1
Investor Presentation: Q2 FY26 14 November 2025
Page 2
©2023 Glenmark Pharmaceuticals Ltd. All Rights Reserved2 This document has been prepared by Glenmark Pharmaceuticals Ltd. and the information, statements and analysis made in this document describing the Company’s or its affiliates’ objectives, projections and estimates are forward looking statements. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact, including, but not limited to, those that are identified by the use of words such as “anticipates”,“believes”, “estimates”,“expects”,“intends”,“plans”, “predicts”, “projects”, “aspirations”,“goals”,“aim”,“targets”,“promises” and similar expressions. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements, depending upon, without limitation: • General economic and political conditions in our key markets, government policies and other incidental factors; • Changes in the overall macro-economic parameters including changes in the currency and interest rates either in India and / or globally; • Ability to successfully implement our strategic plan, including research and development efforts; • Changes in laws and regulations that apply to the pharmaceutical industry and its suppliers and customers; and • Increasing competition in and the conditions of our customers, suppliers and the pharmaceutical industry Actual outcomes may vary materially from those indicated in the applicable forward-looking statements, should one or more of such risks and uncertainties materialize. No representation or warranty, either expressed or implied, is provided in relation to this presentation. This presentation should not be regarded by recipients as a substitute for the exercise of their own judgment. The Company undertakes no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Certain information in this document is not audited or reviewed by an auditor or based on Indian Accounting Standards or internationally accepted accounting principles. The reader should not consider such items as an alternative to the audited financial results or other indicators of the Company’s profit, cash flows or financial performance based on applicable accounting standards. This presentation is property of Glenmark Pharmaceuticals Ltd. Do not alter in any way or reproduce without permission. Disclaimer